References
- Dohle GH, Arver S, Bettocchi C, et al. Guidelines on male hypogonadism. European Association of Urology; 2019 [cited 2020 Feb 26]. Available from: https://uroweb.org/guideline/male-hypogonadism/
- Dean JD, McMahon CG, Guay AT, et al. The international society for sexual medicine’s process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med. 2015;12:1660–1686.
- Zarotsky V, Huang MY, Carman W, et al. Systematic literature review of the risk factors, comorbidities and consequences of hypogonadism in men. Andrology. 2014;2:819–834.
- Arver S, Stief C, de la Rosette J, et al. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology. 2018;6:396–407.
- Fountas A, Van Uum S, Karavitak N. Opiate induced endocrinopathy. Published online 2019 Oct 14. DOI: 10.1016/S2213-8587(19)30254-2.
- Wu FCW, Tajar A, Beynon JM, et al. EMAS Group. Identification of late-onset hypogonadism in middle aged and elderly men. N Engl J Med. 2010;363:123–135.
- Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:42411–42447.
- Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl. 2014;16:192–202.
- Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab. 2010;95:1810–1818.
- Anaissie J, DeLay KJ, Wang W, et al. Testosterone deficiency in adults and corresponding treatment patterns across the globe. Transl Androl Urol. 2017;6(2):183–191..
- Khera M, Adaikan G, Buvat J, et al. Diagnosis and treatment of testosterone deficiency: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med. 2016;13:1787–1804.
- Hackett G, Kirby M, Edwards D, et al. The British Society for Sexual Medicine guidelines on adult testosterone deficiency with statements for UK practice. J Sex Med. 2017;14:1504–1523.
- Hackett G, Kirby M, Edwards D, et al. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017;71:e12901.
- Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.
- Lyseng-Williamson KA. Testosterone 2% gel (Testavan®, Testarzon®) in adult male hypogonadism: a profile of its use. Drugs and Ther Perspect. 2019;35(5): 209–8. DOI:10.1007/s40267-019-00627-7.
- Schlich C, Romanelli F. Issues surrounding testosterone replacement therapy. Hosp Pharm. 2016;51(9):712–720.
- Ullah M, Richie DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014;8:101–112.
- Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male: diagnosis, potential benefits, and risk of testosterone replacement therapy. Int J Endocrinol. 2012;2012:625434.
- Olsson H, Sandström R, Neijber A, et al. Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men. Clin Pharmacol Drug Dev. 2014;3(5):358–364..
- Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165:675–685.
- Grabner M, Hepp Z, Raval A, et al. Topical testosterone therapy adherence and outcomes among men with primary or secondary hypogonadism. J Sex Med. 2018;15:148–158.
- Schoenfeld MJ, Shortridge E, Cui Z, et al. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med. 2013;10(5):1401–1409..
- Brambilla DJ, Matsumoto AM, Araujo AB, et al. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94:907–913.
- Efros M, Carrara D, Neijber A, et al. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies. Andrologia. 2016;48:637–645.
- Cunningham G, Belkoff L, Brock G, et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr Pract. 2017;23(5):557–565..
- Belkoff L, Brock G, Carrara D, et al. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men. Phase III open-label studies. Andrologia. 2017;50(1):e12801.
- Testavan patient information leaflet. 2018 Feb [cited 2019 Oct 09]. Available from: https://www.medicines.org.uk/emc/product/9489/pil
- Testavan summary of product characteristics. 2018 Feb [cited 2019 Oct 09]. Available from: https://www.medicines.org.uk/emc/product/9489/smpc
- Food and Drug Administration. UFaD testosterone products: FDA/CDER statement-risk of venous blood clots. 2014 [cited 2020 Feb 26]. Available from: https://wayback.archive-it.org/7993/20170406123836/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm402054.htm
- US Food and Drug Administration (online). FDA DRUG SAFETY COMMUNICATION: FDA cautions about using testosterone products for low testosterone due to aging; required labeling change to inform of possible increased risk of heart attack and stroke with use. 2015 [cited 2020 Feb 25]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due
- Walker RF, Zakai NA, MacLehose RF, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med. 2020;180(2):190–197.
- Glueck CG, Goldenberg N, Wang P. Testosterone therapy, thrombophilia, venous thromboembolism, and thrombotic events. J Clin Med. 2019 Jan;8(1):11.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32.AUA.
- T4DM trial. [cited 2019 Nov 04]. Available from: http://www.t4dm.org.au/
- Tirabassi G, Delli Muti N, Corona G, et al. Androgen receptor gene CAG repeat polymorphism regulates the metabolic effects of testosterone replacement therapy in male postsurgical hypogonadotropic hypogonadism. Int J Endocrinol. 2013;2013:816740.
- Dadhich P, Ramasamy R, Scovell J, et al. Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men. Indian J Urol. 2017;33(3):236–240.
- Healio Endocrine Today (online). Low-dose hCG can prevent sterility in men prescribed testosterone. 2019 Mar 23 [cited 2019 Nov 04]. Available from: https://www.healio.com/endocrinology/reproduction-androgen-disorders/news/online/%7B027a4c7b-74f0-4f3a-a30f-0c24bd4365bd%7D/low-dose-hcg-can-prevent-sterility-in-men-prescribed-testosterone
- US National Library of Medicine. Clinicaltrials.gov. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). [cited 2019 Nov 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03518034
- Healio Endocrine Today (online). FDA approves oral testosterone capsule for men with hypogonadism. 2019 Mar 27 [cited 2019 Nov 04]. Available from: https://www.healio.com/endocrinology/reproduction-androgen-disorders/news/online/%7Be9ea0fe9-a419-415f-a335-a43d81758b04%7D/fda-approves-oral-testosterone-capsule-for-men-with-hypogonadism
- Gronski MA, Grober ED, Gottesman IS. Efficacy of nasal testosterone gel (Natesto®) stratified by baseline endogenous testosterone levels. J Endocr Soc. 2019 Jun 26;3(9):1652–1662.
- Bosworth T. First RCT with aromatase inhibitor for male hypogonadism shows promise. MDEdge (online); 2019 Mar 29 [cited 2019 Nov 04]. Available from: https://www.mdedge.com/endocrinology/article/197821/mens-health/first-rct-aromatase-inhibitor-male-hypogonadism-shows
- Earl JA, Kim ED. Enclomiphine citrate: A treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019 May;14(3):157–165.